Funding profile · Genomics software

Dropprint Genomics

Dropprint raised no disclosed venture round on its own before Immunai bought it in March 2021. No SEC Form D was ever filed under its name. What can be dated is a Y Combinator backing, a reported letter of intent pipeline, and the buyer’s own capital position at the time of the deal.

UndisclosedPrice Immunai paid for Dropprint, Mar 2021
$0Amount reported in a Dropprint SEC Form D, none found
$80.0MImmunai’s total funding at the time of the deal, company reported
$1.0M+Letters of intent Dropprint said it signed in two months, Mar 2020

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Mar 2020 Y Combinator, Winter 2020 Not disclosed Y Combinator YC data
2019 to 2021 Seed or angel funding, if any Not disclosed None named in any source found Not found
Mar 25, 2021 Acquisition by Immunai Not disclosed Immunai, Inc. Independent

What the filings show

No SEC Form D exists for Dropprint Genomics. A search of EDGAR’s company database for “Dropprint” returns no matching companies, and a full text search of every EDGAR filing for “Dropprint” returns zero hits, both run Sep 25, 2026. Immunai, the acquirer, is also not registered with the SEC as a filer, consistent with its status as a privately held company; there is accordingly no 10-K, 10-Q or 8-K to check the deal price against.

Reading the filings

  1. There is nothing to read, and that is itself informative.A company can raise money without ever filing a Form D, either by staying under the pooled thresholds where states historically did not require one, by raising under a private placement exemption other than Regulation D, or simply by taking only a Y Combinator SAFE and never doing an institutional priced round before being bought. Any of those would explain the absence here; the record does not say which.
  2. The buyer had just raised, the target had not disclosed raising.Immunai closed a $60 million Series A about a month before the acquisition and said its total funding stood at $80 million at that point, per Fierce Biotech and GenomeWeb. Dropprint, by contrast, has no total funding figure attached to it in any source found, disclosed or otherwise.
  3. The LOI number is a sales pipeline claim, not capital raised.TechCrunch reported Dropprint had “signed over $1 million in LOIs in two months” at its March 2020 demo day. A letter of intent is not a contract and not revenue, and the figure predates the acquisition by a year with no update found in between.
  4. Deal size cannot be estimated from public numbers.Unlike deals where a target’s revenue or user base lets a reporter back into a rough price, no revenue, a headcount figure independently confirmed, or a valuation figure for Dropprint was found anywhere in the public record.

Commercial signals

Signal Detail Source type
Acquisition Acquired by Immunai, Mar 25, 2021. Terms not disclosed. Independent
Buyer’s capital Immunai: $60M Series A closed Feb 2021, $80M total raised at time of deal. Company-stated
Sales pipeline Over $1M in letters of intent reported two months after launch, Mar 2020. Independent
Team retention Both co-founders joined Immunai’s Machine Learning and Computational Biology team at close; both have since moved on, per LinkedIn. Company-stated

What to watch

  • Any SEC filing that would name Dropprint or the deal price. None exists as of Sep 25, 2026.
  • Whether Immunai’s own capital raising, as a private company, ever surfaces a retrospective valuation for the assets it bought, including Dropprint’s cell database.
  • Confirmation, one way or another, of the disputed third co-founder claim tied to Dropprint’s UCSF origins.

The Dropprint Genomics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • CellChorus: Also in Drug Discovery and Delivery. A University of Houston spinout that films immune cells one at a time and scores how well each one kills
  • CellType: Also in Drug Discovery and Delivery. A two person Yale spinout that translates single cell biology into a language large models can learn, and is using that model to steer a real cancer drug's next act
  • Indee Labs: Also in Drug Discovery and Delivery. A Berkeley company that built a chip the size of a fingernail to push gene editing cargo into immune cells without a virus and without an electric shock
  • Biocartesian: Also in Drug Discovery and Delivery. A two person, YC-backed lab service that turns tissue and cell samples into what it calls digital molecular maps

Sources

  1. Public recordSEC EDGAR company search for “dropprint,” all form typesSEC EDGAR · searched Sep 25, 2026, no results
  2. Public recordSEC EDGAR full text search for “Dropprint”SEC EDGAR · searched Sep 25, 2026, no results
  3. IndependentImmunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlasFierce Biotech, Conor Hale · Mar 25, 2021
  4. IndependentImmunai Acquires Dropprint GenomicsGenomeWeb · Mar 25, 2021
  5. IndependentAll the companies from Y Combinator’s W20 demo day, part IV: healthcare, biotech, fintech and nonprofitsTechCrunch · Mar 17, 2020
  6. IndependentDropprint Genomics company record, Y Combinator databaseYCDB.co · batch W20, archived Mar 31, 2020
  7. CompanyImmunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery CapabilitiesWebWire, company release · Mar 25, 2021
  8. AggregatorDropprint Genomics: Funding, Team & InvestorsStartup Intros · accessed Sep 25, 2026

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Dropprint Genomics. This page is not an offer to sell or a recommendation to buy any security.